Physician profile
Jennifer R Ely
NPI 1467422618
$33,589.65
in general payments reported to CMS, 2019-2025
40 companies · $2,073 in 2025
The $2,073 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $3,832 · 2021: $3,937 · 2022: $7,872 · 2023: $1,594 · 2024: $1,750 · 2025: $2,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,962 · Education: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,962.44 |
| Education | $454.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $14,479.17 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $10,455.39 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Astrazeneca Pharmaceuticals LP | $2,222.97 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,632.70 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $924.55 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $650.07 | 2019-2025 | |
| Genzyme Corporation | $571.09 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $496.25 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $395.34 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Insmed, INC. | $164.85 | 2019-2023 | Arikayce |
| United Therapeutics Corporation | $139.73 | 2019-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $131.16 | 2022-2025 | Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $110.07 | 2024-2025 | Lumryz |
| Genentech USA, INC. | $105.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $102.73 | 2019-2025 | Keytruda, Winrevair |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.